Pharmacy Reimbursement Benchmark: NADAC, AWP, WAC, and MAC Explained

A pharmacy reimbursement benchmark is the pricing reference used to evaluate, compare, or calculate what pharmacies should be paid for prescription drugs. The problem is that several different benchmarks exist, and they do not measure the same thing.

That is why questions about reimbursement often turn into benchmark questions. Before you can decide whether a price is attractive, fair, or risky, you need to know which benchmark is driving the conversation.

If you want a working product path while reading, use search for a specific NDC, compare the full Drug Markets view, or monitor changes via Pricing.

The Four Benchmarks Most Teams Encounter

NADAC

NADAC stands for National Average Drug Acquisition Cost. It is designed to reflect pharmacy acquisition cost more closely than pure manufacturer list-price references.

Best for:

• ●Reimbursement analysis
• ●Pharmacy acquisition-cost benchmarking
• ●Generic market monitoring
• ●Public benchmark-driven research

Learn more in Understanding NADAC Pricing.

AWP

AWP, or Average Wholesale Price, is a long-standing reference benchmark that still appears in contracts and reimbursement formulas. It is widely recognized, but it is not the same as actual acquisition cost.

Best for:

• ●Interpreting legacy contract language
• ●Benchmark comparison
• ●Historical reimbursement structures

For a deeper comparison, see NADAC vs AWP.

WAC

WAC, or Wholesale Acquisition Cost, is a manufacturer list price to wholesalers. It is useful for list-price context, but it is not the same thing as what pharmacies pay.

Best for:

• ●Manufacturer list-price analysis
• ●Commercial pricing context
• ●Explaining differences between list price and acquisition-oriented benchmarks

For more detail, see NADAC vs WAC.

MAC

MAC, or Maximum Allowable Cost, is generally payer- or PBM-specific. It is often used as a reimbursement ceiling for multisource generic drugs.

Best for:

• ●Payer-specific generic reimbursement analysis
• ●Operational reimbursement management
• ●Understanding plan-specific ceiling behavior

Unlike NADAC, AWP, and WAC, MAC is often less transparent and more organization-specific.

Why Benchmark Selection Changes the Analysis

Two teams can look at the same drug and reach very different conclusions simply because they are using different benchmarks.

For example:

• ●A contract analyst may need AWP because that is how the agreement is written
• ●A reimbursement analyst may need NADAC because it is closer to acquisition cost
• ●A pricing strategist may need WAC for list-price context
• ●A pharmacy operator may need to understand MAC if that is the payment ceiling in practice

The benchmark is not a footnote. It defines what problem you are solving.

Three Benchmark Questions From the Current NADAC Update

1. Has a market reset enough to affect reimbursement analysis?

That is the kind of question NADAC answers best. The recent ticagrelor move is a good example because the market-level change is immediately relevant to reimbursement pressure and acquisition benchmarking.

2. Is the signal coming from one supplier or from the broader market?

That is where manufacturer activity matters. A supplier-level move like Royal Pharmaceuticals at -15.79% average change is not the same question as a contract benchmark reference. It is a market-structure question.

3. Is this just one drug, or is a whole class moving?

That is where class-level screens matter. A move like Vitamin D2 Analog at +11.61% is useful because it tells you to zoom out before drawing conclusions from a single NDC.

Why NADAC Is So Important in Reimbursement Workflows

NADAC matters because it is often the most actionable public benchmark for understanding acquisition-cost pressure. If the question is whether reimbursement is keeping up with market conditions, NADAC is often closer to the operational reality than AWP or WAC alone.

That is why many users start with an NADAC-oriented workflow:

1. ●Search the exact product in search
2. ●Compare the full Drug Market
3. ●Review the participating Manufacturers
4. ●Check surrounding movement in Trends

How to Choose the Right Benchmark for the Job

Choose NADAC when the question is about acquisition-cost reality or reimbursement pressure.

Choose AWP when the question is about a contract written around AWP formulas.

Choose WAC when the question is about manufacturer list-price context.

Choose MAC when the question is about a payer-specific reimbursement ceiling for generics.

In practice, many teams need to understand more than one benchmark. The important part is not mixing them up. The wrong benchmark can make a ticagrelor-style market move look theoretical when it is actually operational.

How NADAC Intelligence Supports Benchmark Analysis

NADAC Intelligence is useful when you need to see how a benchmark behaves inside the actual product and market structure.

Use it to:

• ●Look up a specific product with search
• ●Compare related products in Drug Markets
• ●Inspect supplier context in Manufacturers
• ●Screen category movement in Therapeutic Classes
• ●Monitor recent shifts in Trends

If that turns into an ongoing operational need, evaluate Pricing.

Frequently Asked Questions

What is the most common pharmacy reimbursement benchmark?

There is no single answer because different contracts and workflows use different references. NADAC, AWP, WAC, and MAC all appear in practice.

Is NADAC the same as MAC?

No. NADAC is a public benchmark meant to reflect pharmacy acquisition cost more closely. MAC is usually a payer- or PBM-specific ceiling for reimbursement.

Why is NADAC often preferred for reimbursement analysis?

Because it is often more reflective of pharmacy acquisition-cost conditions than pure list-price benchmarks.

What should I do after choosing a benchmark?

Apply it to a real product and market. Start with search, compare the full Drug Market, and inspect related Manufacturers.

Final Takeaway

The right pharmacy reimbursement benchmark depends on the decision you are making. NADAC, AWP, WAC, and MAC all matter, but they answer different questions. The real mistake is using the right benchmark for the wrong question.

Use NADAC Intelligence to connect benchmark theory to real products, markets, manufacturers, and trends so reimbursement analysis stays grounded in actual market structure.